Immunic, Inc. (IMUX) financial statements (2020 and earlier)

Company profile

Business Address AM KLOPFERSPITZ 19
MARTINSRIED, 82152
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments2913576083102
Cash and cash equivalents2913576083102
Restricted cash and investments    12
Receivables0     
Other current assets1     
Other undisclosed current assets211111
Total current assets:3214586185105
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment012343
Intangible assets, net (including goodwill)33     
Goodwill33     
Other noncurrent assets000000
Total noncurrent assets:3412343
TOTAL ASSETS:6615606489108
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities62105613
Accounts payable201111
Accrued liabilities329559
Employee-related liabilities     3
Deferred revenue and credits   0
Other liabilities100000
Other undisclosed current liabilities     (3)
Total current liabilities:73105710
Noncurrent Liabilities
Long-term debt and lease obligation1     
Operating lease, liability1
Liabilities, other than long-term debt  0000
Deferred revenue and credits0   
Other liabilities   000
Other undisclosed noncurrent liabilities 0 0  
Total noncurrent liabilities:100000
Total liabilities:83106711
Stockholders' equity
Stockholders' equity attributable to parent581250588298
Common stock000000
Additional paid in capital120350346302285248
Accumulated other comprehensive income (loss)(1)00000
Accumulated deficit(60)(337)(296)(244)(203)(151)
Total stockholders' equity:581250588298
TOTAL LIABILITIES AND EQUITY:6615606489108

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:  (1)(1)(1) 
Operating expenses(37)(42)(53)(41)(52)(50)
Other undisclosed operating income  111 
Operating loss:(37)(42)(53)(41)(52)(50)
Nonoperating income211003
Investment income, nonoperating011000
Other nonoperating income (expense)20(0)000
Net loss attributable to parent:(35)(41)(52)(41)(52)(48)
Preferred stock dividends and other adjustments     (9)
Net loss available to common stockholders, diluted:(35)(41)(52)(41)(52)(57)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(35)(41)(52)(41)(52)(48)
Other comprehensive income (loss)(1)0(0)0(0)(0)
Comprehensive loss:(35)(41)(52)(41)(52)(48)
Other undisclosed comprehensive loss, net of tax, attributable to parent (0)    
Comprehensive loss, net of tax, attributable to parent:(35)(41)(52)(41)(52)(48)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: